Galderma stock gets a stronger 2026 growth outlook

Published on 10/07/2026 at 14:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Galderma stock carries first-half sales growth of 24.6 percent and a 19-21 percent 2026 outlook. Core EBITDA margin reached 25.6 percent in H1.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma stock (ISIN CH1335392721) was trading at CHF 161.45 on SIX at 2:11 p.m. CEST on October 7, 2026, up CHF 0.10 or 0.06 percent from the prior close. The company entered the session with a raised 2026 growth outlook and a fast-expanding dermatology portfolio.

Guidance moves to 19-21 percent

According to Business Wire on September 21, 2026, Galderma raised its full-year 2026 net sales growth guidance to 19-21 percent at constant currency from 17-20 percent previously. The company reaffirmed its core EBITDA margin guidance at 26 percent for the year.

The change followed first-half net sales growth of 24.6 percent at constant currency. That comparison matters because the new guidance range sits below the first-half pace, implying a more demanding second-half comparison rather than a fresh acceleration built into the forecast.

Margins strengthen with Nemluvio

Galderma reported USD 3.1 billion in first-half 2026 net sales, according to Yahoo Finance. Core EBITDA reached USD 802 million, up 42.8 percent year over year, while the core EBITDA margin expanded to 25.6 percent from the first half of 2025.

Core net income rose 66.3 percent to USD 547 million, and core EPS increased 68.5 percent to USD 2.34 in the same period. The operating leverage is central to the stock story because profit growth is running faster than sales growth.

Restylane adds portfolio depth

In a release dated October 6, 2026, Galderma said Restylane had reached 77 million treatments worldwide across 30 years. The company also highlighted new approvals for Restylane Shaype in the European Union, a new syringe in the EU, United States and Canada, and Restylane Volyme in the United States.

The product expansion gives the growth guidance a concrete operating basis, but the valuation still depends on execution across injectable aesthetics, dermatological skincare and therapeutic dermatology. Galderma joined the SMI on September 21, 2026, broadening its visibility among Swiss large-cap investors.

Stock remains below yearly high

Galderma stock was trading at CHF 161.45 on SIX on October 7, 2026, with an intraday range of CHF 160.00 to CHF 162.05 and volume of 101,713 shares. Its 52-week range was CHF 134.70 to CHF 188.25, while market capitalization stood at CHF 37.6 billion.